Compare · KLTO vs RVMD
KLTO vs RVMD
Side-by-side comparison of Klotho Neurosciences Inc. (KLTO) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KLTO and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD carries a market cap of $37.27B.
- Over the past year, KLTO is up 12.3% and RVMD is up 154.3% - RVMD leads by 142.0 points.
- RVMD has hit the wire 12 times in the past 4 weeks while KLTO has been quiet.
- RVMD has more recent analyst coverage (25 ratings vs 0 for KLTO).
- Company
- Klotho Neurosciences Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- -
- $37.27B
- 1M return
- +113.82%
- -8.97%
- 1Y return
- +12.34%
- +154.29%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2020
- News (4w)
- 0
- 12
- Recent ratings
- 0
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest KLTO
- Why a $35 Million Greenland Rare Earth Deal Just Put One Small-Cap on Every Investor's Radar
- Klotho Neurosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Klotho Neurosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML
- Klotho Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026
- Chief Financial Officer Leblanc Jeff was granted 2,500,000 shares, increasing direct ownership by 272% to 3,420,342 units (SEC Form 4)
- Director El-Dada Riad Hussein was granted 350,000 shares (SEC Form 4)
- Director Zentman Samuel M was granted 350,000 shares, increasing direct ownership by 48% to 1,086,440 units (SEC Form 4)
- Director Hirschman Shalom was granted 350,000 shares, increasing direct ownership by 63% to 908,873 units (SEC Form 4)
Latest RVMD
- Director Borisy Alexis gifted 10,625 shares, decreasing direct ownership by 0.45% to 2,329,450 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 35,750 shares at a strike of $29.19 and sold $6,724,688 worth of shares (35,750 units at $188.10) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Mancini Anthony exercised 811 shares at a strike of $33.70 and sold $162,200 worth of shares (811 units at $200.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress
- Officer Mancini Anthony sold $431,947 worth of shares (2,310 units at $186.99) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Participate in November 2026 Investor Conferences
- Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026